A top official at pharmaceutical giant Johnson & Johnson dismissed questions on a recent earnings call about the drug price reform debate in Washington, saying that the company is “responsible” in its pricing.

As part of the question and answer period during the company’s third quarter earnings call in October, one questioner asked Johnson & Johnson Chief Financial Officer Dominic Caruso where he sees the drug pricing reform debate in Washington going and if the company was planning a pledge, similar to one made by many firms in the 1990s, to not raise drug prices beyond the cost of inflation.

“Despite significant media attention on drug pricing, there really isn’t a consensus on policy solutions that would lower prices without negatively lowering innovation,” Caruso said.

After recalling the industry’s collaboration on the Affordable Care Act, Caruso then told the questioner that the “real answer to this dilemma is to monitor and provide outcome-based metrics and not simply focus only on price.”

Finally, Caruso, in response to a question about the industry voluntarily restraining the prices of its own drugs, explained that he would rather focus on justifying the current prices of drugs. “I think we’re very responsible in our drug pricing. And we tend to support the price of our drugs with strong economic data,” he said. “So rather than pledge to a particular number I think it’s important that we continue to develop robust data that provides a solid foundation for the value that our products provide the health care system.”

Listen to Caruso’s full remarks below: